Unity Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UBX research report →
About the company
Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
- CEO
- Anirvan Ghosh
- IPO
- 2018
- Employees
- 16
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $3.44M
- P/E
- -0.13
- P/S
- 0.00
- P/B
- 0.52
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -148.97%
- ROIC
- -96.71%
- Revenue
- $0 · 0.00%
- Net Income
- $-25,990,000 · 34.80%
- EPS
- $-1.54 · 42.96%
- Op Income
- $-31,171,000
- FCF YoY
- 43.76%
- 52W High
- $3.10
- 52W Low
- $0.10
- 50D MA
- $0.66
- 200D MA
- $1.23
- Beta
- 1.06
- Avg Volume
- 761.63K
Get TickerSpark's AI analysis on UBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 27, 25 | Jalbert Craig R. | other | 0 |
| Apr 2, 25 | Nguyen Alexander Hieu | sell | 17,852 |
| Apr 2, 25 | Sullivan Lynne Marie | sell | 21,867 |
| Apr 2, 25 | Ghosh Anirvan | sell | 96,797 |
| Mar 28, 25 | Nguyen Alexander Hieu | other | 73,000 |
| Mar 28, 25 | Nguyen Alexander Hieu | other | 44,000 |
| Mar 27, 25 | Nguyen Alexander Hieu | sell | 1,954 |
| Mar 28, 25 | Sullivan Lynne Marie | other | 65,000 |
| Mar 28, 25 | Sullivan Lynne Marie | other | 106,000 |
| Mar 28, 25 | Ghosh Anirvan | other | 286,000 |
Our UBX coverage
Recent articles, reports, and earnings notes.
No research on UBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UBX report →Similar companies
Peers in the same neighborhood.